Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases

Collaboration consolidates Everest's leadership in the renal space Everest Medicines will pay Sinovent and SinoMab USD $12 million in upfront and up to $549 million in total development, regulatory, and commer...

Full "IntellAsia: Resources" article